Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies
Open Access

Is Balneotherapy Protective Against Oxidative Stress? A Pilot Study

AGNES SZENCZI, IVAN PETER, NORA NUSSER, ZENO AJTAY, KATALIN SZENDI, KAROLY BERENYI, ZOLTAN HORVATH-SZALAI, BALAZS SZIRMAY, ANDRAS SUMEGI, ADRIENN HANZEL and BALAZS NEMETH
In Vivo March 2023, 37 (2) 858-861; DOI: https://doi.org/10.21873/invivo.13153
AGNES SZENCZI
1Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IVAN PETER
2Harkány Spa Hospital, Harkány, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORA NUSSER
2Harkány Spa Hospital, Harkány, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZENO AJTAY
2Harkány Spa Hospital, Harkány, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATALIN SZENDI
1Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: katalin.szendi@pte.hu
KAROLY BERENYI
1Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZOLTAN HORVATH-SZALAI
3Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BALAZS SZIRMAY
3Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDRAS SUMEGI
1Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ADRIENN HANZEL
1Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BALAZS NEMETH
1Department of Public Health Medicine, Medical School, University of Pécs, Pécs, Hungary;
2Harkány Spa Hospital, Harkány, Hungary;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: This study aimed to research the effects of Harkány healing water on oxidative stress. The study was performed in a randomized, placebo-controlled, double-blind setup. Patients and Methods: Twenty patients with psoriasis who underwent a 3-week-long inward balneotherapy-based rehabilitation were enrolled. Psoriasis Area and Severity Index (PASI) score and Malondialdehyde (MDA) – a marker of oxidative stress - were determined, on admission and before discharge. Patients were treated with dithranol. Results: The mean PASI score - determined on admission and before discharge - decreased significantly after the 3-week-long rehabilitation 8.17 vs. 3.51 (p<0.001). The baseline MDA value of patients with psoriasis was significantly higher compared to controls (3.0±3.5 vs. 8.4±7.4) (p=0.018). MDA levels of patients receiving placebo water increased significantly compared to MDA levels of patients receiving healing water (p=0.049). Conclusion: The effectiveness of dithranol resides in the formation of reactive oxygen species. No increased oxidative stress was found in the patients treated with healing water, thus healing water seems to be protective against oxidative stress. However, further research is needed to confirm these preliminary results.

Key Words:
  • Psoriasis
  • rehabilitation
  • balneotherapy
  • dithranol
  • malondialdehyde
  • oxidative stress

The worldwide prevalence of psoriasis in adults varies between 0.91% and 8.5% with an incidence of 78.9/100,000 to 230/100,000 (1). Psoriasis is an incurable lifelong disease with considerable negative effects on quality of life (2). One of the most important discoveries of recent years is that patients with psoriasis have significantly increased risk of developing cardiovascular diseases, diabetes, depression, and inflammatory diseases (3-6). The pathophysiology of psoriasis is not fully understood. However, several factors are thought to play a role in the development of psoriasis. Besides genetical background and general risk factors (stress, obesity, smoking, alcohol consumption), the inordinate activation of the immune system has been identified as a key factor in the development of psoriasis (7-9). Previous studies indicated that oxidative stress plays a major role in the long-term adverse effects of psoriasis. Malondialdehyde (MDA) is one of the most widespread oxidative stress markers. Asha et al., compared the MDA levels of healthy volunteers to MDA levels of patients suffering from psoriasis. Significantly higher MDA levels were found in patients with psoriasis compared to controls. Moreover, MDA levels were found to be positively correlated with the severity of psoriasis (10).

Topical agents (e.g., vitamin D analogues, corticosteroids, dithranol) play a major role in psoriasis treatment. Systemic medications and natural agents (e.g., peloid, UV-light, salt, healing water) are also important parts of the treatment (11, 12).

The aim of this study was to report a balneotherapy-based psoriasis rehabilitation protocol and assess its effectiveness. This study also aimed to research the effects of Harkány healing water on oxidative stress. The study was performed in a randomized, placebo-controlled, double-blind setup.

Patients and Methods

The study was a randomised (1:1 for two groups) double-blind, placebo-controlled study conducted at the Harkány Spa Hospital; Harkány, Hungary in the ISO 9001 accredited Balneology Unit from January 2022 to November 2022. Informed written consent to participate in the study and to publish the collected data was obtained from every patient. The study protocol was approved by the Regional Ethics Committee of University of Pécs, Pécs, Hungary (Permission No.: 7740-PTE 2019), in accordance with the Declaration of Helsinki. This trial was prospectively registered at ClinicalTrials.gov (ID: NCT04290143).

Inclusion criteria included the onset of psoriatic skin lesions, and over 18 years of age. Exclusion criteria included having received any kind of balneotherapy within 1 year before admission, receiving any kind of biological therapy, discontinuance of rehabilitation, the inability to enter and exit the treatment tub unassisted, and withdrawal of consent. Additionally, individuals diagnosed with cancer or kidney injury were also excluded.

Patients with psoriasis were treated with Harkány healing water. Control patients were treated with placebo water in a bathtub for 30 min, twice a day, 6 days a week, during a 3-week-long inward rehabilitation.

The severity and extent of psoriasis were measured by the Psoriasis Area and Severity Index (PASI). PASI score was calculated on admission and before discharge, after completing the 3-week-long rehabilitation. To rule out interobserver error, PASI score was assessed by the same dermatologist. Besides PASI score high-sensitivity C-reactive protein (hs-CRP), and MDA was measured from venous blood samples taken on admission and before discharge. Currently, there is no validated reference interval for MDA, thus 30 healthy volunteers were enrolled as MDA controls. CRP levels were determined in our University’s clinical laboratory with automated analysers according to the manufacturer’s protocol (Cobas 8000; Roche Diagnostics GmbH, Mannheim, Germany). MDA analysis was performed with the Lipid Peroxidation (MDA) Assay Kit (Sigma-Aldrich Co., St. Louis, MO, USA) according to the manufacturer’s protocol. Samples were stored at −80°C until analysis.

Besides these objective markers of disease severity, authors aimed to find out how psoriasis affects the patients’ everyday life. Questionnaires regarding the patients’ complaints and overall physical wellbeing [e.g., Dermatology Life Quality Index (DLQI), 36-Item Short Form Survey (SF-36)] were filled in on admission and before discharge.

Besides healing water or placebo water, all patients received physiotherapy, electrotherapy, ultrasound therapy, UVB phototherapy, and magnet therapy. Dithranol was used 5 times a week in an ascending concentration from 0.5% to 6% according to the current dermatological status of the patient. The psoriasis rehabilitation protocol of our hospital is detailed in a previous publication (13). Details and validation of the placebo water are described in our previously published work (14).

Statistical analysis. Statistical analysis was performed with IBM SPSS Statistics for Windows Version 22 (IBM Corp., New York, NY, USA). According to Shapiro-Wilk test, MDA values showed normal distribution, thus an error bar was used to demonstrate the results. Wilcoxon signed-rank test was used to compare the MDA values and questionnaire results. Differences between MDA values measured after admission and before discharge were compared with t-test. To reveal correlations, the Pearson’s correlation test was used. All p-values less than 0.05 were considered statistically significant.

Results

A total of 112 patients with psoriasis were screened during the enrolment period. Out of the 112 patients, 22 were eligible for the study. Two patients dropped out due to infection. Finally, 20 patients completed the study. Clinical characteristics of the subjects are shown in Table I. All patients were diagnosed with psoriasis vulgaris and completed a 3-week-long inward dermatological rehabilitation. Positive family history was found in 30% of the patients. Regarding the complications of psoriasis, 30% of the patients suffered from atrophia psoriatica and 10% from arthritis psoriatica.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Clinical characteristics of the involved patients.

Patients received a combination of spa treatments during the 3-week-long inward rehabilitation. Besides placebo or healing water, all patients received dithranol, UVB phototherapy, physiotherapy, and electrotherapy. All patients’ PASI score - calculated on admission and before discharge - decreased significantly after the 3-week-long rehabilitation (8.17 vs. 3.51) (p<0.001).

Regarding the entire patient population, we found no significant difference between the CRP value measured at admission and before discharge. When examining the changes in CRP values within the two groups, we found no significant difference between the CRP values measured at admission and before discharge. The baseline MDA value of psoriatic patients was significantly higher compared to that of healthy controls (3.0±3.5 vs. 8.4±7.4; p=0.018). MDA levels of patients receiving placebo water increased significantly compared to MDA levels of patients receiving healing water (p=0.049) (Figure 1, Table II).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Malondialdehyde (MDA) concentration of patients treated with healing water and placebo water.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Malondialdehyde (MDA) concentration of patients treated with healing water and placebo water.

All patients’ DLQI total score decreased significantly at discharge compared to admission (p=0.037). When comparing the changes of DLQI total scores of placebo patients to healing water patients, no significant differences were observed.

Regarding all patients no significant differences were found between SF-36 total score measured at discharge and SF-36 total score measured at admission. No significant differences were found between SF-36 total score measured at admission and at discharge, neither in the placebo group nor in the healing water group.

Discussion

This study demonstrated that during the 3-week-long inward balneotherapy-based rehabilitation the MDA levels of patients receiving placebo water increased significantly compared to the MDA levels of patients receiving healing water. Currently, MDA does not have a reference interval, thus the control group was comprised of healthy volunteers. MDA levels were significantly higher in psoriatic patients compared to healthy controls. MDA is a well-known oxidative stress marker, capable of representing the current oxidative status of the patients (15). Dithranol is one of the most effective and most used topical antipsoriatic agent. The effectiveness of dithranol resides in the formation of reactive oxygen species (ROS) as the cells forming the psoriatic plaque are susceptible to oxidative stress (16, 17). On the other hand, recent studies have shown that excessive oxidative stress could play a role in the development of certain diseases e.g., cardiovascular diseases (18, 19), Alzheimer’s disease (20), and various types of cancer (21, 22). The dithranol mediated inflammatory response was already proven in in vitro and also in murine models (23, 24). According to our results, healing water seems to be capable of neutralizing the effects of oxidative stress caused by dithranol, similar to the study of Varga et al. (25) where healing water was shown to be protective against the oxidative stress caused by UV irradiation in vitro.

Regarding the ethical issues of placebo treatment, it can be stated that similar improvements were found - both in subjective (DLQI and SF-36) and objective (PASI) parameters - in both groups. These results/parameters demonstrate the appropriateness of the protocol for further studies.

In conclusion, healing water seems to be capable of reducing the harmful effects of dithranol. This pilot study was a part of a five-year long complex research program focusing on balneotherapy. According to these preliminary results the study design is feasible. Our research group will continue the patient enrolment to increase the sample size.

Acknowledgements

The Authors would like to thank all the nurses of the Dermatology ward for their invaluable help. This work was financially supported by the National Research, Development and Innovation Office – NKFIH (FK_19. ID: FK 131531). The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Footnotes

  • Authors’ Contributions

    AS: Writing draft; IP: dermatological background; NN: providing institutional background; ZA: validation; KSZ: project management, digitalization; ZHSZ: laboratory background; BSZ: laboratory background; AS: patient enrolment; AH: patient enrolment; KB: statistical analysis; BN: conceptualizing, organization, reviewing and editing manuscript.

  • Conflicts of Interest

    The Authors declare that there is no conflict of interest regarding the publication of this paper.

  • Received December 22, 2022.
  • Revision received December 31, 2022.
  • Accepted January 2, 2023.
  • Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Parisi R,
    2. Symmons DP,
    3. Griffiths CE,
    4. Ashcroft DM and Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team
    : Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133(2): 377-385, 2013. PMID: 23014338. DOI: 10.1038/jid.2012.339
    OpenUrlCrossRefPubMed
  2. ↵
    1. Griffiths CE and
    2. Barker JN
    : Pathogenesis and clinical features of psoriasis. Lancet 370(9583): 263-271, 2007. PMID: 17658397. DOI: 10.1016/S0140-6736(07)61128-3
    OpenUrlCrossRefPubMed
  3. ↵
    1. Rapp SR,
    2. Feldman SR,
    3. Exum ML,
    4. Fleischer AB Jr. and
    5. Reboussin DM
    : Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41(3 Pt 1): 401-407, 1999. PMID: 10459113. DOI: 10.1016/s0190-9622(99)70112-x
    OpenUrlCrossRefPubMed
    1. Smith CH and
    2. Barker JN
    : Psoriasis and its management. BMJ 333(7564): 380-384, 2006. PMID: 16916825. DOI: 10.1136/bmj.333.7564.380
    OpenUrlFREE Full Text
    1. Asefi M,
    2. Vaisi-Raygani A,
    3. Khodarahmi R,
    4. Nemati H,
    5. Rahimi Z,
    6. Vaisi-Raygani H,
    7. Tavilani H and
    8. Pourmotabbed T
    : Methylentetrahydrofolatereductase (rs1801133) polymorphism and psoriasis: contribution to oxidative stress, lipid peroxidation and correlation with vascular adhesion protein 1, preliminary report. J Eur Acad Dermatol Venereol 28(9): 1192-1198, 2014. PMID: 24118377. DOI: 10.1111/jdv.12262
    OpenUrlCrossRefPubMed
  4. ↵
    1. Ikonomidis I,
    2. Makavos G,
    3. Papadavid E,
    4. Varoudi M,
    5. Andreadou I,
    6. Gravanis K,
    7. Theodoropoulos K,
    8. Pavlidis G,
    9. Triantafyllidi H,
    10. Parissis J,
    11. Paraskevaidis I,
    12. Rigopoulos D and
    13. Lekakis J
    : Similarities in coronary function and myocardial deformation between psoriasis and coronary artery disease: the role of oxidative stress and inflammation. Can J Cardiol 31(3): 287-295, 2015. PMID: 25660150. DOI: 10.1016/j.cjca.2014.11.002
    OpenUrlCrossRefPubMed
  5. ↵
    1. Huerta C,
    2. Rivero E and
    3. Rodríguez LA
    : Incidence and risk factors for psoriasis in the general population. Arch Dermatol 143(12): 1559-1565, 2007. PMID: 18087008. DOI: 10.1001/archderm.143.12.1559
    OpenUrlCrossRefPubMed
    1. Nestle FO,
    2. Kaplan DH and
    3. Barker J
    : Psoriasis. N Engl J Med 361(5): 496-509, 2009. PMID: 19641206. DOI: 10.1056/NEJMra0804595
    OpenUrlCrossRefPubMed
  6. ↵
    1. Péter I,
    2. Jagicza A,
    3. Ajtay Z,
    4. Kiss I and
    5. Németh B
    : [Psoriasis and oxidative stress]. Orv Hetil 157(45): 1781-1785, 2016. PMID: 27817235. DOI: 10.1556/650.2016.30589
    OpenUrlCrossRefPubMed
  7. ↵
    1. Asha K,
    2. Singal A,
    3. Sharma SB,
    4. Arora VK and
    5. Aggarwal A
    : Dyslipidaemia & oxidative stress in patients of psoriasis: Emerging cardiovascular risk factors. Indian J Med Res 146(6): 708-713, 2017. PMID: 29664028. DOI: 10.4103/ijmr.IJMR_717_16
    OpenUrlCrossRefPubMed
  8. ↵
    1. Rahman M,
    2. Alam K,
    3. Ahmad MZ,
    4. Gupta G,
    5. Afzal M,
    6. Akhter S,
    7. Kazmi I,
    8. Jyoti,
    9. Ahmad FJ and
    10. Anwar F
    : Classical to current approach for treatment of psoriasis: a review. Endocr Metab Immune Disord Drug Targets 12(3): 287-302, 2012. PMID: 22463723. DOI: 10.2174/187153012802002901
    OpenUrlCrossRefPubMed
  9. ↵
    1. Menter A,
    2. Korman NJ,
    3. Elmets CA,
    4. Feldman SR,
    5. Gelfand JM,
    6. Gordon KB,
    7. Gottlieb A,
    8. Koo JY,
    9. Lebwohl M,
    10. Lim HW,
    11. Van Voorhees AS,
    12. Beutner KR,
    13. Bhushan R and American Academy of Dermatology
    : Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 60(4): 643-659, 2009. PMID: 19217694. DOI: 10.1016/j.jaad.2008.12.032
    OpenUrlCrossRefPubMed
  10. ↵
    1. Péter I,
    2. Jagicza A,
    3. Ajtay Z,
    4. Boncz I,
    5. Kiss I,
    6. Szendi K,
    7. Kustán P and
    8. Németh B
    : Balneotherapy in psoriasis rehabilitation. In Vivo 31(6): 1163-1168, 2017. PMID: 29102940. DOI: 10.21873/invivo.11184
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Nemeth B,
    2. Hanzel A,
    3. Berenyi K,
    4. Peter I,
    5. Hetesi C,
    6. Ajtay Z,
    7. Szenczi A,
    8. Sumegi A and
    9. Szendi K
    : A new and validated, randomised, controlled placebo water development trial for medicinal water-based research. In Vivo 35(5): 2881-2888, 2021. PMID: 34410982. DOI: 10.21873/invivo.12577
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Del Rio D,
    2. Stewart AJ and
    3. Pellegrini N
    : A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 15(4): 316-328, 2005. PMID: 16054557. DOI: 10.1016/j.numecd.2005.05.003
    OpenUrlCrossRefPubMed
  13. ↵
    1. Müller K
    : Antipsoriatic anthrones: aspects of oxygen radical formation, challenges and prospects. Gen Pharmacol 27(8): 1325-1335, 1996. PMID: 9304402. DOI: 10.1016/s0306-3623(96)00075-4
    OpenUrlCrossRefPubMed
  14. ↵
    1. Müller K
    : Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals. Biochem Pharmacol 53(9): 1215-1221, 1997. PMID: 9214681. DOI: 10.1016/s0006-2952(96)00732-0
    OpenUrlCrossRefPubMed
  15. ↵
    1. Kattoor AJ,
    2. Pothineni NVK,
    3. Palagiri D and
    4. Mehta JL
    : Oxidative stress in atherosclerosis. Curr Atheroscler Rep 19(11): 42, 2017. PMID: 28921056. DOI: 10.1007/s11883-017-0678-6
    OpenUrlCrossRefPubMed
  16. ↵
    1. Steven S,
    2. Frenis K,
    3. Oelze M,
    4. Kalinovic S,
    5. Kuntic M,
    6. Bayo Jimenez MT,
    7. Vujacic-Mirski K,
    8. Helmstädter J,
    9. Kröller-Schön S,
    10. Münzel T and
    11. Daiber A
    : Vascular inflammation and oxidative stress: Major triggers for cardiovascular disease. Oxid Med Cell Longev 2019: 7092151, 2019. PMID: 31341533. DOI: 10.1155/2019/7092151
    OpenUrlCrossRefPubMed
  17. ↵
    1. Chen Z and
    2. Zhong C
    : Oxidative stress in Alzheimer’s disease. Neurosci Bull 30(2): 271-281, 2014. PMID: 24664866. DOI: 10.1007/s12264-013-1423-y
    OpenUrlCrossRefPubMed
  18. ↵
    1. Ding DN,
    2. Xie LZ,
    3. Shen Y,
    4. Li J,
    5. Guo Y,
    6. Fu Y,
    7. Liu FY and
    8. Han FJ
    : Insights into the role of oxidative stress in ovarian cancer. Oxid Med Cell Longev 2021: 8388258, 2021. PMID: 34659640. DOI: 10.1155/2021/8388258
    OpenUrlCrossRefPubMed
  19. ↵
    1. Gorrini C,
    2. Harris IS and
    3. Mak TW
    : Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12(12): 931-947, 2013. PMID: 24287781. DOI: 10.1038/nrd4002
    OpenUrlCrossRefPubMed
  20. ↵
    1. Lange RW,
    2. Hayden PJ,
    3. Chignell CF and
    4. Luster MI
    : Anthralin stimulates keratinocyte-derived proinflammatory cytokines via generation of reactive oxygen species. Inflamm Res 47(4): 174-181, 1998. PMID: 9628260. DOI: 10.1007/s000110050313
    OpenUrlCrossRefPubMed
  21. ↵
    1. Schmidt KN,
    2. Podda M,
    3. Packer L and
    4. Baeuerle PA
    : Antipsoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes. J Immunol 156(11): 4514-4519, 1996. PMID: 8666828.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Varga C,
    2. László M,
    3. Gerencsér G,
    4. Gyöngyi Z and
    5. Szendi K
    : Natural UV-protective organic matter in thermal water. J Photochem Photobiol B 144: 8-10, 2015. PMID: 25662041. DOI: 10.1016/j.jphotobiol.2015.01.007
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

In Vivo: 37 (2)
In Vivo
Vol. 37, Issue 2
March-April 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Is Balneotherapy Protective Against Oxidative Stress? A Pilot Study
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Is Balneotherapy Protective Against Oxidative Stress? A Pilot Study
AGNES SZENCZI, IVAN PETER, NORA NUSSER, ZENO AJTAY, KATALIN SZENDI, KAROLY BERENYI, ZOLTAN HORVATH-SZALAI, BALAZS SZIRMAY, ANDRAS SUMEGI, ADRIENN HANZEL, BALAZS NEMETH
In Vivo Mar 2023, 37 (2) 858-861; DOI: 10.21873/invivo.13153

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Is Balneotherapy Protective Against Oxidative Stress? A Pilot Study
AGNES SZENCZI, IVAN PETER, NORA NUSSER, ZENO AJTAY, KATALIN SZENDI, KAROLY BERENYI, ZOLTAN HORVATH-SZALAI, BALAZS SZIRMAY, ANDRAS SUMEGI, ADRIENN HANZEL, BALAZS NEMETH
In Vivo Mar 2023, 37 (2) 858-861; DOI: 10.21873/invivo.13153
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy
  • Forensic Medical Examination After Sexual Violence: Implications Based on Victims’ Perceptions
  • Albumin–derived Neutrophil-to-Lymphocyte Ratio Score as a Marker of Nivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study
Show more Clinical Studies

Similar Articles

Keywords

  • Psoriasis
  • rehabilitation
  • balneotherapy
  • dithranol
  • malondialdehyde
  • oxidative stress
In Vivo

© 2023 In Vivo

Powered by HighWire